FDA warns Colonial Dames of manufacturing violations and unapproved acne drug claims for Oxygenetix.
What happened
FDA inspected the drug manufacturing facility in Commerce, CA, from April 4 to 12, 2023, and reviewed the company’s May 2, 2023 response to FDA’s inspection observations (Form FDA 483). Investigators found inadequate production records and validation, poor cleaning and equipment conditions, an unqualified water system, weak quality-unit oversight, and inadequate stability testing. FDA also reviewed the website and found acne-treatment and other claims for Oxygenetix products that make them unapproved new drugs and misbranded, and the company failed to meet drug listing obligations.
What FDA found
The company lacked adequate written production and process controls; batch records omitted equipment identification, mixing speeds and times, and component addition rates, and process validation support was missing.
21 CFR 211.100(a)Cleaning procedures were not validated, cleaning records were inadequate, and equipment, utensils, and production areas were unclean with residue.
21 CFR 211.67(a) and (b)The water system used for cleaning and formulation was not qualified or properly monitored, and rust on its holding tank showed an ongoing maintenance issue.
21 CFR 211.63The quality control unit did not adequately oversee standard operating procedures, validation, supplier qualification, quality agreements, annual product review, or complaints.
21 CFR 211.22Stability testing was inadequate; data did not support the 3-year expiry, an out-of-specification salicylic acid result was not fully investigated, and microbiological methods were not validated for drugs.
21 CFR 211.166(a)FDA cited unapproved new drug and misbranding violations for Oxygenetix acne products due to acne-treatment and other claims, non-monograph active ingredients, time-release salicylic acid claims, and failure to list the drugs.
FD&C Act sections 505(a), 502(ee), 510(j)(1), and 502(o)
What FDA wants
FDA asks the company to provide detailed corrective-action plans and supporting evidence for the production, cleaning, water-system, quality-unit, stability, and drug approval/listing violations. The provided letter text does not state a response deadline.
Who should pay attention
- OTC acne drug manufacturers and marketers
- contract manufacturers and brands using shared equipment or water systems
- companies making acne or cosmetic products with drug-like claims
This is a summary. Read the original letter on fda.gov.